1. 1) Hardy KJ, Hawkey PM, Gao F, Oppenheim BA. Methicillin resistant Staphylococcus aureus in the critically ill. Br. J. Anaesth., 92, 121–130 (2004).
2. 2) Thompson DS, Workman R, Strutt M. Contribution of acquired methicillin-resistant Staphylococcus aureus bacteremia to overall mortality in a general intensive care unit. J. Hosp. Infect., 70, 223–227 (2008).
3. 3) Matsumoto K, Kanazawa N, Ikawa K, Fukamizu T, Shigemi A, Yaji K, Shimodozono Y, Morikawa N, Takeda Y, Yamada K. Determination of teicoplanin trough concentration target and appropriate total dose during the first 3 days: a retrospective study in patients with MRSA infections. J. Infect. Chemother., 16, 193–199 (2010).
4. 4) Kanazawa N, Matsumoto K, Ikawa K, Fukamizu T, Shigemi A, Yaji K, Shimodozono Y, Morikawa N, Takeda Y, Yamada K. An initial dosing method for teicoplanin based on the area under the serum concentration time curve required for MRSA eradication. J. Infect. Chemother., 17, 297–300 (2011).
5. 5) Dong YL, Dong HY, Hu SS, Wang X, Wei YX, Wang MY, Dong WH, Yao HP, You HS, Xing JF. An assessment of teicoplanin use and monitoring serum levels in a Chinese teaching hospital. Int. J. Clin. Pharmacol. Ther., 49, 14–22 (2011).